All In Biotech

Drug Trial Radar · NCT04996797

A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005)

A Phase 2, Multi-Center, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Induction Therapy With PRA023 in Subjects With Moderately to Severely Active Ulcerative Colitis

Last checked: Nov 19, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 178 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

178

Actual

Start

Jul 14, 2021

Primary completion

Jun 6, 2023

Study completion Jul 14, 2025

Sponsor

Sponsor type
Industry
First posted
Aug 9, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety and efficacy of tulisokibart in participants with moderately to severely active Ulcerative Colitis (UC). After the completion of the 12-week induction, all participants have the option to continue in the open-label extension for up to 170 weeks.

Conditions

  • Ulcerative Colitis

Interventions

  • TulisokibartDrug

    Administered by IV infusion

  • Companion Diagnostic (CDx) TestingDevice

    PRA023 CDx Genotyping Assay

  • PlaceboOther

    Placebo administered by IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants in Cohort 1 Achieving Clinical RemissionTime frame: Baseline and Week 12
  2. Percentage of Participants Who Experienced an Adverse Event (AE)Time frame: Up to ~14 weeks
  3. Percentage of Participants Who Discontinued Due to an AETime frame: Up to ~14 weeks
  4. Percentage of Participants Who Had One or More Serious Adverse EventsTime frame: Up to ~14 weeks

Locations

88 sites in 12 countries. Site status is shown where the registry gives one.

  • Prometheus Biosciences Selected Center

    Mobile, Alabama

  • Prometheus Biosciences Selected Site

    Phoenix, Arizona

  • Prometheus Biosciences Selected Site

    Sun City, Arizona

  • Prometheus Biosciences Selected Site

    Los Angeles, California

  • Prometheus Biosciences Selected Site

    Los Angeles, California

  • Prometheus Biosciences Selected Site

    San Diego, California

  • Prometheus Biosciences Selected Site

    Bristol, Connecticut

  • Prometheus Biosciences Selected Site

    Atlanta, Georgia

  • Prometheus Biosciences Selected Site

    Arlington Heights, Illinois

  • Prometheus Biosciences Selected Site

    Glenview, Illinois

  • Prometheus Biosciences Selected Site

    Gurnee, Illinois

  • Prometheus Biosciences Selected Site

    Kansas City, Kansas

  • Prometheus Biosciences Selected Site

    Liberty, Kansas

  • Prometheus Biosciences Selected Site

    Baton Rouge, Louisiana

  • Prometheus Biosciences Selected Site

    Chevy Chase, Maryland

  • Prometheus Biosciences Selected Site

    Chesterfield, Michigan

  • Prometheus Biosciences Selected Site

    Lebanon, New Hampshire

  • Prometheus Biosciences Selected Site

    New York, New York

  • Prometheus Biosciences Selected Site

    New York, New York

  • Prometheus Biosciences Selected Site

    Dublin, Ohio

  • Prometheus Biosciences Selected Site

    Germantown, Tennessee

  • Prometheus Biosciences Selected Site

    Bedford, Texas

  • Prometheus Biosciences Selected Site

    Lubbock, Texas

  • Prometheus Biosciences Selected Site

    Mansfield, Texas

  • Prometheus Biosciences Selected Site

    San Antonio, Texas

  • Prometheus Biosciences Selected Site

    Southlake, Texas

  • Prometheus Biosciences Selected Site

    Tyler, Texas

  • Prometheus Biosciences Selected Site

    Charlottesville, Virginia

  • Prometheus Biosciences Selected Site

    Tacoma, Washington

  • Prometheus Biosciences Selected Site

    Woodville, Adelaide, Australia

  • Prometheus Biosciences Selected Site

    Kingswood, New South Wales, Australia

  • Prometheus Biosciences Selected Site

    Old Toongabbie, New South Wales, Australia

  • Prometheus Biosciences Selected Site

    South Brisbane, Queensland, Australia

  • Prometheus Biosciences Selected Site

    Woolloongabba, Queensland, Australia

  • Prometheus Biosciences Selected Site

    Adelaide, South Australia, Australia

  • Prometheus Biosciences Selected Site

    Fitzroy, Victoria, Australia

  • Prometheus Biosciences Selected Site

    Melbourne, Victoria, Australia

  • Prometheus Biosciences Selected Site

    Leuven, Belgium

  • Prometheus Biosciences Selected Site

    Liège, Belgium

  • Prometheus Biosciences Selected Site

    Calgary, Alberta, Canada

Showing 40 of 88 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.